Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Large Volume Increase – Here’s Why

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw an uptick in trading volume on Thursday . 458 shares were traded during trading, an increase of 4% from the previous session’s volume of 440 shares.The stock last traded at $16.10 and had previously closed at $16.5450.

Ono Pharmaceutical Stock Down 2.7%

The firm’s 50 day moving average price is $13.97 and its two-hundred day moving average price is $12.41. The firm has a market capitalization of $7.56 billion, a PE ratio of 18.09 and a beta of 0.25. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical (OTCMKTS:OPHLF) last posted its quarterly earnings data on Monday, February 2nd. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11. Ono Pharmaceutical had a net margin of 12.29% and a return on equity of 7.76%. The company had revenue of $892.70 million during the quarter, compared to analysts’ expectations of $727.58 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.